Our study has laid a foundation for further elucidating the molecular mechanisms of PODNL1 related regulatory network in tumor progression and developing PODNL1 as a potential tumor matrix-mediated biomarker for immunotherapy and prognosis in a pan-cancer setting. This evidence concerns the gene PODNL1 and neoplasm.